|Awarded On||February 21, 2019|
|Title||A Randomized, Controlled Trial Comparing the Immunogenicity of 2 Doses Versus 3 Doses of the 9-Valent HPV Vaccine in Males and Females 15 to 26 Years of Age|
|Award Mechanism||Individual Investigator Research Awards for Prevention and Early Detection|
|Institution/Organization||The University of Texas Medical Branch at Galveston|
|Principal Investigator/Program Director||Abbey Berenson|
|Cancer Sites||Cervix Uteri, Head and Neck, Penis|
The HPV vaccine is recommended for all adolescents and young adults to prevent several types of cancer. If the vaccine series is started by 14 years of age, only 2 doses are recommended. However, if the vaccine series is started at age 15 or greater, 3 doses are recommended. It is possible that 2 doses are actually sufficient in older teens and young adults, but no one has tested this hypothesis to see if it is true. We will conduct a clinical trial to examine the immune response of older teens and young adults who receive 3 doses of the HPV vaccine as compared to the immune response of those who receive only 2 doses. We hypothesize that the immune responses will be similar, demonstrating th...